Vaccine (Adenoviral vector) · Immune activation, directed at HPV E6/E7 · developed by ImmunityBio
hAd5-HPV is an adenovirus-based vaccine encoding HPV E6/E7 antigens, administered subcutaneously. It is being studied in HPV-positive oropharyngeal squamous cell carcinoma and head and neck cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07628062 | Phase 2 | HPV-Positive Oropharyngeal Squamous Cell Carcinoma | Not yet recruiting | IBRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Head and Neck CancerHPV-Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal Squamous Cell Carcinoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.
See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IBRX catalysts and pipeline →